GLP1-GIP-Amylin tri-agonist
Obesity
Phase 2Active
Key Facts
About Novo Nordisk
Novo Nordisk has established itself as the dominant player in the diabetes and obesity treatment markets through its innovative GLP-1 receptor agonist portfolio. The company's purpose is to drive change to defeat diabetes and other serious chronic diseases, with a robust pipeline spanning multiple therapeutic areas including cardiovascular disease, rare blood disorders, and metabolic diseases. Recent regulatory approvals, including Wegovy HD (semaglutide 7.2 mg) providing 20.7% mean weight loss, demonstrate continued innovation and market expansion. The company maintains a strong financial position and is expanding global access to its treatments through strategic partnerships.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Zepbound) | Eli Lilly | Approved |
| APJ Program | BioAge Labs | Preclinical |
| Wegovy HD (semaglutide 7.2mg) | Novo Nordisk | Approved |
| Amylin analogue (subcutaneous) | Novo Nordisk | Phase 1 |
| VK2735 (subcutaneous) | Viking Therapeutics | Phase 3 |
| VK2735 (oral) | Viking Therapeutics | Phase 1/2 |
| GSBR-1290 | Structure Therapeutics | Phase 2 |
| LTSE-2578 | Structure Therapeutics | Preclinical |
| Survodutide (BI 456906) | Zealand Pharma | Phase 3 |
| ZP8396 | Zealand Pharma | Preclinical/Phase 1 |
| Pemvidutide (ALT-801) | Altimmune | Phase 2 |
| PL7737 | Palatin Technologies | Preclinical |